Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2019 16:05 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Reports Second Quarter 2019 Financial Results and Recent Highlights

-- Topline data from pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis on track for Q4 2019 -- -- Completed enrollment in LUMINA 1 Phase II trial of CCR2...
August 01, 2019 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Present at the Canaccord Genuity 39th Annual Growth Conference

MOUNTAIN VIEW, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the...
July 31, 2019 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Hold Second Quarter 2019 Financial Results Conference Call on Monday, August 5, 2019

MOUNTAIN VIEW, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2019 financial results will be released after market...
June 11, 2019 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., June 11, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two...
May 06, 2019 16:05 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights

-- Succession of topline data readouts expected, starting with Pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis in Q4 2019 -- -- Conference call today at 5:00...
April 29, 2019 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Hold First Quarter 2019 Financial Results Conference Call on Monday, May 6, 2019

MOUNTAIN VIEW, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2019 financial results will be released after market...
April 02, 2019 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Present at the H.C. Wainwright Global Life Sciences Conference

MOUNTAIN VIEW, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the...
March 28, 2019 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors

MOUNTAIN VIEW, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), announced today that, effective March 27, 2019, Rita Jain, M.D., Senior Vice President and Chief Medical...
March 11, 2019 16:05 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights

-- Strong Progress Across Company’s Orphan Disease Franchise of Novel Renal and Dermal Therapeutics -- -- Pivotal top-line data expected from ADVOCATE Phase III trial of C5a receptor inhibitor...
March 04, 2019 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Hold Fourth Quarter 2018 Financial Results Conference Call on Monday, March 11, 2019

MOUNTAIN VIEW, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter 2018 financial results will be released after market...